Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation

Leukemia

Volumn 25, Issue 6, 2011, Pages 932-938

  Peric, Z ^a   Cahu, X ^a,c   Chevallier, P ^a,b   Brissot, E ^a   Malard, F ^a   Guillaume, T ^a,b   Delaunay, J ^a   Ayari, S ^a   Dubruille, V ^a   Le Gouill, S ^a,b   Mahe, B ^a   Gastinne, T ^a   Blin, N ^a   Saulquin, B ^a,d   Harousseau, J L ^a,b,d   Moreau, P ^a,b   Milpied, N ^a,e   Coste Burel, M ^a,b   Imbert Marcille, B M ^a,b   Mohty, M ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d Centre Régional de Lutte Contre le Cancer CRLCC   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

EBV; LPD; reduced intensity conditioning; rituximab

Indexed keywords

AMSACRINE; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY; TREOSULFAN; VIRUS DNA;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MALE; MICROBIAL KINETICS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; VIRUS REACTIVATION;

EID: 79958149913     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.26     Document Type: Article

References (47)

1. Giralt S, Estey E, AlbitarM, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536. (Pubitemid 27260263)
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. (Pubitemid 28078275)
3. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
4. Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Curr Opin Oncol 2009; 21(Suppl 1): S3-S5.
5. Mohty M, Rocha V, Chevallier P, Harousseau JL, Nagler A. Reduced-intensity conditioning for allogeneic stem cell transplantation: .10. years later. Curr Opin Oncol 2009; 21(Suppl 1): S1.
6. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054. (Pubitemid 27172593)
7. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
8. Micallef IN, Chhanabhai M, Gascoyne RD, Shepherd JD, Fung HC, Nantel SH et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998; 22: 981-987. (Pubitemid 28543060)
9. Hale G, Waldmann H. Risks of developing Epstein-Barr virusrelated lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998; 91: 3079-3083. (Pubitemid 28227562)
10. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216. (Pubitemid 29467666)
11. Gross TG, SteinbuchM, DeFor T, Shapiro RS,McGlave P, Ramsay NK et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251-258. (Pubitemid 29078338)
12. Juvonen E, Aalto SM, Tarkkanen J, Volin L, Mattila PS, Knuutila S et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32: 97-102. (Pubitemid 36850286)
13. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008.
14. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44. (Pubitemid 40299772)
15. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654-3661. (Pubitemid 28225732)
16. Hoshino Y, Kimura H, Tanaka N, Tsuge I, Kudo K, Horibe K et al. Prospective monitoring of the Epstein-Barr virus DNA by a realtime quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol 2001; 115: 105-111. (Pubitemid 32995102)
17. Gartner BC, Schafer H, Marggraff K, Eisele G, Schafer M, Dilloo D et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002; 40: 351-358. (Pubitemid 34130852)
18. van Esser JW, Van Der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972-978.
19. Lankester AC, van Tol MJ, Vossen JM, Kroes AC, Claas E. Epstein- Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease. Blood 2002; 99: 2630-2631. (Pubitemid 34525464)
20. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981. (Pubitemid 38596322)
21. Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG. Monitoring and preemptive rituximab therapy for epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010; 16: 287-291.
22. Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229-239. (Pubitemid 40562444)
23. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874-2880.
24. Cahu X, Rialland F, Touzeau C, Chevallier P, Guillaume T, Delaunay J et al. Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. Biol Blood Marrow Transplant 2009; 15: 1531-1537.
25. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reducedintensity preparative regimen. Blood 2003; 102: 470-476. (Pubitemid 36841962)
26. Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 28-34.
27. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177. (Pubitemid 37428382)
28. Chevallier P, Hebia-Fellah I, Planche L, Guillaume T, Bressolette- Bodin C, Coste-Burel M et al. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source. Bone Marrow Transplant 2010; 45: 1204-1211.
29. Bressollette-Bodin C, Coste-Burel M, Besse B, Andre-Garnier E, Ferre V, Imbert-Marcille BM. Cellular normalization of viral DNA loads on whole blood improves the clinical management of cytomegalovirus or Epstein Barr virus infections in the setting of pre-emptive therapy. J Med Virol 2009; 81: 90-98.
30. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001; 28: 909-915. (Pubitemid 33130231)
31. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. JASA 1999; 94: 496-509.
32. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388-1395.
33. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149.
34. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versushost disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multicentre, randomised phase II-III trial. Lancet 2005; 366: 733-741. (Pubitemid 41207235)
35. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD task force and the mayo clinic organized international consensus development meeting. Transplantation 1999; 68: 1517-1525.
36. van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113: 814-821. (Pubitemid 32524408)
37. Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77: 76-84.
38. Stevens SJ, Verschuuren EA, Verkuujlen SA, Van den Brule AJ, Meijer CJ, Middeldorp JM. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831-840. (Pubitemid 34428672)
39. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second European conference on infections in leukemia. Bone Marrow Transplant 2009; 43: 757-770.
40. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in posttransplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112-118. (Pubitemid 32995103)
41. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-1505. (Pubitemid 30099868)
42. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000.
43. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-274. (Pubitemid 46852438)
44. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935.
45. Savani BN, Pohlmann PR, Jagasia M, Chinratanalab W, Kassim A, Engelhardt B et al. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD? Blood 2009; 113: 6263-6264.
46. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387-1394. (Pubitemid 46965279)
47. Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reducedintensity preparative regimen. Bone Marrow Transplant 2004; 33: 839-846. (Pubitemid 38519246)